Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 23.53% | 2.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.53% | 2.27% | |||
| Cost of Revenue | 37.38% | -6.90% | |||
| Gross Profit | 22.31% | 3.16% | |||
| SG&A Expenses | 7.86% | 6.64% | |||
| Depreciation & Amortization | 1.08% | -2.18% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.13% | -1.92% | |||
| Operating Income | 19.21% | 10.00% | |||
| Income Before Tax | 17.64% | 20.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.26% | 20.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.26% | 20.69% | |||
| EBIT | 19.21% | 10.00% | |||
| EBITDA | 20.19% | 10.45% | |||
| EPS Basic | 20.19% | 21.22% | |||
| Normalized Basic EPS | 20.36% | 9.91% | |||
| EPS Diluted | 20.47% | 20.94% | |||
| Normalized Diluted EPS | 20.36% | 9.91% | |||
| Average Basic Shares Outstanding | 1.17% | 0.68% | |||
| Average Diluted Shares Outstanding | 1.17% | 0.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||